内甲素-1具有独特的节氧效应,通过增加隔离的老鼠心脏的收缩效率来增加氧气节约效应
Y Takeuchi1, Y Kihara, K Inagaki
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Circulation
|March 21, 2001
概括
内甲素-1 (ET-1) 通过ET(A) 受体增强心脏收缩性和收缩效率. ET-1的这种节氧效应可能在ET-1积聚的失灵心脏中具有适应性.
科学领域:
- 心血管生理学心血管生理学
- 心脏活力学是什么心脏活力学
- 分子心脏病学分子心脏病学
背景情况:
- 内甲素-1 (ET-1) 对心脏能量的确切影响仍未完全阐明.
- 了解ET-1的作用对于开发针对心脏功能障碍的向治疗至关重要.
研究的目的:
- 为了研究ET-1对心脏收缩率和心肌氧消耗 (MVO(2) 在隔离的老鼠心脏的影响.
- 确定ET-1对心脏能量影响的特定受体通路和机制.
主要方法:
- 隔离,冠状动脉透的老鼠心脏被用于测量左心室收缩率 (E(max),压力体积面积 (PVA) 和MVO(2).
- 在ET-1注射前后进行测量,随后的实验涉及受体阻断剂 (ET(A),ET(B),高和氧化合成酶抑制.
主要成果:
- ET-1显著增加了E(max) 和MVO(2),同时提高了约22%的收缩效率 (1/S).
- 这些效应主要通过ET(A) 受体进行介导,因为它们被ET(A) 受体阻断剂消除.
- ET-1对收缩效率的影响独立于Na ((+) /H ((+) 交换器和氧化合成酶通路.
结论:
- ET-1,作用于ET(A) 受体,以节氧的方式提高心肌的化学机械效率.
- 这种独特的特性表明ET-1在心肌衰竭的背景下具有潜在的适应作用,其局部水平可能会增加.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...